On September 27, 2023 BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, reported the presentation of a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA (Press release, BeyondSpring Pharmaceuticals, SEP 27, 2023, View Source;utm_medium=rss&utm_campaign=beyondspring-and-leading-cancer-center-to-present-poster-at-sitcs-38th-annual-meeting [SID1234635445]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster, titled, "Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade," will be presented by Dr. Steven H. Lin, MD., Ph.D., physician-scientist, radiation oncologist and professor who specializes in thoracic malignancies at The University of Texas MD Anderson Cancer Center.
Additional presentation details are as follows:
Poster Session Date / Time: Saturday, November 4th, 2023, at 9 a.m. to 8:30 p.m. PDT
Location: San Diego Convention Center, Exhibit Halls A and B1
Type of Presentation: Poster Presentation
Abstract No.: 732